Enzymotec Expands Activities in China

22 Mar 2012 --- Global biotech company commences operations in Shanghai - Local and regional customers to benefit.

--- Enzymotec, a dynamic, biotech company and a leading global supplier of lipid-based products, announced the opening of its Shanghai office.

The new branch of Enzymotec is aimed at supporting the company's growing business activities in China as well as providing its existing customers with expert, on-hand customer service.

With a foothold in over 40 countries, Enzymotec develops and manufactures lipid-based biofunctional and nutraceutical ingredients and end products that are based on sophisticated proprietary technologies.

"This is a significant step forward for Enzymotec, which has successfully expanded its commercial activities over the last few years," says Dr. Ariel Katz, CEO of Enzymotec.  "South East Asia in general and China in particular have become key markets for us due to the economic developments in the region. In addition, we believe that maintaining a local presence is highly important and fits our global marketing strategy."

Enzymotec's innovative solutions are divided into three business segments: 

  • Infant Nutrition Division  –  Producer of InFatTM, a clinically-proven ingredient in infant formulas that mimics the fat of human milk. InFatTM is marketed through Advanced Lipids AB, a joint venture of AAK and Enzymotec. Advanced Lipids is a primary supplier of fat ingredients for leading infant formulas in China. 
  • Bioactive Division  –  A major provider of lipid-based products providing high quality solutions for the body and mind. 
  • VAYA Pharma – A researched-based, specialty pharmaceutical division dedicated to the discovery, development, manufacturing and marketing of innovative and effective, clinically tested and safe natural lipid-based medicines.

 

To contact our editorial team please email us at editorial@cnsmedia.com

Enzymotec

Collapse

Who We Are

Enzymotec develops and manufactures nutritional ingredients and medical foods, driven by a deep core of cutting-edge, proprietary technologies. Since its establishment in 1998, the company has enjoyed accelerated growth, generating impressive sales worldwide, by launching a diverse portfolio of innovative products. Our two business segments leverage our lipid-related expertise: Nutrition and Pharma.

Enzymotec's diverse range of products span the entire human life-cycle - from infancy to old age, providing key ingredients for use in infant formula and nutritional supplements, as well as branded medical foods.

Enzymotec's multi-disciplinary team, including scientists, engineers and business development professionals, have an outstanding track-record in turning advanced lipid science into commercially attractive, nutritional solutions, constantly enriching our unique cluster of technology and expertise.

What We Do

We develop clinically-validated products including bio-functional, lipid-based compounds that address a wide spectrum of growing consumer demands, such as optimal development, supplementation for nutritional deficiencies and needs, and the management of medical disorders and diseases.

The comprehensive solutions we develop and manufacture are sold to major consumer companies through our global sales and marketing infrastructure.

How We Do It

We employ proprietary technologies to modify lipids harvested from natural sources, transforming these raw materials into unique and clinically-proven lipid based products. These products are familiar to the human body and possess beneficial secondary characteristics, such as extended shelf life and improved scent or taste profile.

Our Source of Competitive Advantage:

• Safe and clinically-proven products supported by proprietary technology and R&D expertise.

• Experienced leadership and scientific advisory boards.

• Diversified business model

• Strong customer relationships and partnerships

• Integrated scalable platform and product offering, based on state-of-the-art production capabilities.

Related Articles

Business News

Icon gets reduced sugar option: Cadbury Dairy Milk with 30 percent less sugar to debut in UK & Ireland

23 Jul 2018 --- A sugar-reduced version of the iconic British chocolate bar Dairy Milk will hit the shelves next year as confectionery giants Cadbury progresses with its initiative to drive down sugar in its products. In a bid to help consumers manage their sugar intake and launched against a backdrop of changing consumer preferences, Cadbury Dairy Milk will be available in a new bar with 30 percent less sugar as from 2019.

Business News

Start-up success: “Think audaciously, be bold and take risks,” says Practical Innovation

23 Jul 2018 --- The role that start-ups have in future product development success was a key theme at IFT in Chicago where inspiring innovation “to feed the future and beyond” was in the spotlight. Continuously evolving consumer demands, together with the need to achieve a sustainable future, are helping to fuel start-ups with convention-challenging innovation, Innova Market Insights reported at the event.

Business News

Extended shelf-life tomatoes: Arcadia and Shriram reach milestone

23 Jul 2018 --- Arcadia Biosciences, Inc., an agricultural food ingredient company, and Shriram Bioseed, a leading research and hybrid seed development company, have announced the achievement of a key milestone in developing extended shelf life (ESL) tomatoes. Bioseed has field tested Arcadia’s ESL technology in multiple tomato hybrid backgrounds in multiple locations and seasons. Significant and consistent improvements in field yield and fruit quality, such as firmness, shelf-life and color development, were observed. These new hybrids are in the pre-commercial, wide area field testing stage with anticipated launch in 2019.

Business News

The consolidating ingredients sector: Ingredion convergence epitomizes a tightening sector

23 Jul 2018 --- The integration of several portfolios into a single larger ingredient entity was a key theme at the IFT 2018 Food Expo in Chicago last week. The relatively small trade show floor was a reminder of how many previous exhibiting companies have been swallowed up over recent years, in order to be integrated into the likes of DSM (e.g. Martek, Ocean Nutrition Canada and Fortitech), Kerry (e.g. Ganeden, Red Arrow and Biothera), ADM (Wild Flavors) and IFF (Ottens Flavors and David Michael). Naturex (currently being acquired by Givaudan) could be the next to disappear from a show floor, amid a consolidating ingredients world, where questions must soon be raised about a growing lack of competition and diversity in ultimate holding companies.

Food Ingredients News

Sensient execs on Mazza buy: “We want to take everything out of the botanical”

20 Jul 2018 --- Sensient is eyeing the newly acquired botanical extraction company Mazza Innovation as a strategic pillar for all of its business operations, including colors and flavors. Presented under the new name of “Sensient Natural Extraction” and continuing to operate out of Canada, the new business unit provides a clean extraction opportunity for Sensient Technologies Corp. The acquisition will offer opportunities in sustainability, cost reduction and clean label, as the entire botanical being used can be broken down and distributed among the diverse companies that comprise Sensient.

More Articles